Literature DB >> 1557950

Secondary changes of the motor endplate in Lambert-Eaton myasthenic syndrome: a quantitative study.

L F Hesselmans1, F G Jennekens, J Kartman, J H Wokke, M de Visser, E G Klaver-Krol, M DeBaets, F Spaans, H Veldman.   

Abstract

Underlying the Lambert-Eaton myasthenic syndrome (LEMS) is a decrease in the release of the neurotransmitter acetylcholine. Only few reports on light and transmission electron microscopical observations of motor endplates in LEMS are available and changes reported so far differ from those found in experimental blocking of acetylcholine release. We performed a quantitative study on intercostal muscle biopsies of five patients. The main light microscopical finding was an enlargement of the area of contact between nerve and muscle, which was interpreted as a compensatory phenomenon. At the ultrastructural level we found the mean postsynaptic area and membrane length of the neuromuscular junctions to be decreased, putatively due to small postsynaptic regions of newly created neuromuscular junctions. The secondary changes in LEMS endplates as seen in this study are similar to those reported in experimental blocking of acetylcholine release.

Entities:  

Mesh:

Year:  1992        PMID: 1557950     DOI: 10.1007/bf00308480

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  23 in total

1.  Motor nerve sprouting and acetylcholine receptors.

Authors:  A Pestronk; D B Drachman
Journal:  Science       Date:  1978-03-17       Impact factor: 47.728

2.  Morphological changes in the human end plate with age.

Authors:  J H Wokke; F G Jennekens; C J van den Oord; H Veldman; L M Smit; G J Leppink
Journal:  J Neurol Sci       Date:  1990-03       Impact factor: 3.181

3.  An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse.

Authors:  L W Duchen
Journal:  J Neurol Sci       Date:  1971-09       Impact factor: 3.181

4.  [Eaton-Lambert myasthenic syndrome: clinical, electrophysiologic, histological and ultrastructural study].

Authors:  P Castaigne; P Rondot; M Fardeau; H P Cathala; J L Ribadeau-Dumas; P Dudognon
Journal:  Rev Neurol (Paris)       Date:  1977-10       Impact factor: 2.607

5.  Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.

Authors:  A Vincent; S G Cull-Candy; J Newsom-Davis; A Trautmann; P C Molenaar; R L Polak
Journal:  Muscle Nerve       Date:  1981 Jul-Aug       Impact factor: 3.217

6.  Recently recognized congenital myasthenic syndromes: (a) end-plate acetylcholine (ACh) esterase deficiency (b) putative abnormality of the ACh induced ion channel (c) putative defect of ACh resynthesis or mobilization - clinical features, ultrastructure and cytochemistry.

Authors:  A G Engel; E H Lambert; D M Mulder; M R Gomez; J N Whitaker; Z Hart; K Sahashi
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

7.  Acetylcholine content and release in denervated or botulinum poisoned rat skeletal muscle.

Authors:  R L Polak; L C Sellin; S Thesleff
Journal:  J Physiol       Date:  1981       Impact factor: 5.182

8.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

9.  Morphological and histochemical changes of motor units in myasthenia.

Authors:  C Coërs; N Telerman-Toppet
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

10.  A myasthenic syndrome with congenital paucity of secondary synaptic clefts: CPSC syndrome.

Authors:  L M Smit; G Hageman; H Veldman; P C Molenaar; B S Oen; F G Jennekens
Journal:  Muscle Nerve       Date:  1988-04       Impact factor: 3.217

View more
  1 in total

Review 1.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.